| Literature DB >> 33918583 |
Si'an Fang1, Yuhao Jiang1, Di Xiao1, Xuran Zhang1, Qianqian Gan1, Qing Ruan1, Junbo Zhang1.
Abstract
To develop potential technetium-99m single-photon emission computed tomography (SPECT) imaging agents for bacterial infection imaging, the novel norfloxacin isonitrile derivatives CN4NF and CN5NF were synthesized and radiolabeled with a [99mTc][Tc(I)]+ core to obtain [99mTc]Tc-CN4NF and [99mTc]Tc-CN5NF. These compounds were produced in high radiolabeling yields and showed hydrophilicity and good stability in vitro. The bacterial binding assay indicated that [99mTc]Tc-CN4NF and [99mTc]Tc-CN5NF were specific to bacteria. Compared with [99mTc]Tc-CN4NF, biodistribution studies of [99mTc]Tc-CN5NF showed a higher uptake in bacteria-infected tissues than in turpentine-induced abscesses, indicating that [99mTc]Tc-CN5NF could distinguish bacterial infection from sterile inflammation. In addition, [99mTc]Tc-CN5NF had higher abscess/blood and abscess/muscle ratios. SPECT image of [99mTc]Tc-CN5NF showed that there was a clear accumulation in the infection site, suggesting that it could be a potential bacterial infection imaging radiotracer.Entities:
Keywords: infection imaging; isonitriles; norfloxacin; quinolones; technetium-99m
Year: 2021 PMID: 33918583 PMCID: PMC8069222 DOI: 10.3390/pharmaceutics13040518
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Structures of CNnNF (n = 4 or 5) and [99mTc]Tc-CNnNF (n = 4 or 5).
Scheme 1Synthetic route of CN4NF and CN5NF.
Figure 2(a) HPLC profiles of [99mTc]Tc-CN4NF and (b) [99mTc]Tc-CN5NF.
Figure 3In vitro binding of [99mTc]Tc-CN4NF and [99mTc]Tc-CN5NF. n = 6, * p < 0.05.
Biodistribution of [99mTc]Tc-CN4NF and [99mTc]Tc-CN5NF in mice (% ID/g ± SD, n = 4).
| [99mTc]Tc-CN4NF | [99mTc]Tc-CN5NF | |||||||
|---|---|---|---|---|---|---|---|---|
| Mice with Bacterial Infection | Mice with Turpentine-Induced Abscess | Mice with Bacterial Infection | Mice with Turpentine-Induced Abscess | |||||
| Tissue | 0.5 h | 2 h | 4 h | 4 h | 0.5 h | 2 h | 4 h | 4 h |
| Heart | 1.90 ± 0.23 | 0.74 ± 0.15 | 0.75 ± 0.12 | 1.05 ± 0.06 | 1.77 ± 0.35 | 0.98 ± 0.16 | 0.87 ± 0.10 | 1.12 ± 0.44 |
| Liver | 12.55 ± 1.08 | 14.02 ± 1.04 | 14.18 ± 0.39 | 14.21 ± 1.26 | 14.13 ± 1.43 | 15.51 ± 0.88 | 16.23 ± 1.17 | 16.63 ± 0.53 |
| Lung | 4.99 ± 0.28 | 1.76 ± 0.15 | 1.46 ± 0.03 | 1.61 ± 0.37 | 3.59 ± 0.60 | 1.75 ± 0.49 | 0.93 ± 0.08 | 1.26 ± 0.70 |
| Kidneys | 6.53 ± 1.15 | 5.12 ± 0.61 | 6.00 ± 0.24 | 5.42 ± 0.71 | 5.71 ± 0.80 | 4.28 ± 0.24 | 3.87 ± 0.07 | 2.97 ± 1.03 |
| Spleen | 5.97 ± 1.12 | 7.11 ± 1.44 | 5.11 ± 0.82 | 6.79 ± 2.05 | 4.89 ± 0.83 | 3.80 ± 0.66 | 2.98 ± 0.75 | 3.46 ± 0.83 |
| Stomach | 1.59 ± 0.14 | 1.60 ± 0.26 | 1.37 ± 0.51 | 1.01 ± 0.17 | 5.02 ± 0.82 | 4.53 ± 0.75 | 4.32 ± 0.88 | 1.15 ± 0.24 |
| Bone | 12.08 ± 1.43 | 12.31 ± 1.05 | 14.13 ± 1.10 | 12.20 ± 2.23 | 8.18 ± 0.91 | 9.33 ± 1.45 | 8.25 ± 0.20 | 8.91 ± 1.10 |
| Muscle | 2.71 ± 0.37 | 2.12 ± 0.65 | 1.51 ± 0.46 | 1.10 ± 0.30 | 1.43 ± 0.16 | 0.98 ± 0.14 | 0.56 ± 0.23 | 0.73 ± 0.08 |
| Intestine | 1.41 ± 0.11 | 0.80 ± 0.16 | 0.73 ± 0.18 | 0.81 ± 0.16 | 1.52 ± 0.18 | 0.64 ± 0.22 | 0.68 ± 0.22 | 0.44 ± 0.16 |
| Abscess | 1.89 ± 0.73 | 1.15 ± 0.27 | 0.87 ± 0.06 | 0.53 ± 0.03 | 1.94 ± 0.19 | 1.47 ± 0.08 | 1.17 ± 0.05 | 0.69 ± 0.37 |
| Blood | 2.17 ± 0.38 | 0.74 ± 0.11 | 0.58 ± 0.20 | 0.47 ± 0.08 | 1.87 ± 0.23 | 0.74 ± 0.07 | 0.45 ± 0.03 | 0.45 ± 0.10 |
| Thyroid (%ID) | 0.10 ± 0.02 | 0.10 ± 0.03 | 0.08 ± 0.02 | 0.07 ± 0.01 | 0.05 ± 0.01 | 0.05 ± 0.01 | 0.03 ± 0.01 | 0.03 ± 0.00 |
| T/N 1 | 0.70 | 0.54 | 0.58 | 0.48 | 1.36 | 1.50 | 2.08 | 0.95 |
| T/B 2 | 0.87 | 1.55 | 1.50 | 1.12 | 1.04 | 1.98 | 2.62 | 1.55 |
1 T/N = abscess/muscle ratio. 2 T/B = abscess/blood ratio.
Figure 4Comparison of the biodistribution in mice of [99mTc]Tc-CN4NF and [99mTc]Tc-CN5NF. (a) Infection uptake of the complexes at 4 h post-injection; (b) target/non-target ratio of the complexes at 4 h post-injection.
Figure 5Half-body SPECT image of [99mTc]Tc-CN5NF in female Kunming mice bearing infection and inflammation at 2 h post-injection (visual imaging).